A Phase I Study of INC280 in Japanese Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 22 Jun 2016
At a glance
- Drugs Capmatinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Novartis
- 17 Jun 2016 Status changed from active, no longer recruiting to completed.
- 14 Jan 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 01 Mar 2015 Planned End Date changed from 1 Oct 2015 to 1 Apr 2016 as reported by ClinicalTrials.gov record.